Showing 2664 results
- Media Release /Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…
- Media Release /Die Aktionäre bewilligen die 22. Dividendenerhöhung in Folge. Für 2018 wird die Dividende auf CHF 2.85 (+2%) je Aktie erhöht, was einer Rendite von 3,1% und einem Anteil von etwa 57% des freien…
- Media Release /Les actionnaires approuvent la 22e hausse consécutive du dividende à CHF 2.85 (+2%) par action pour 2018, soit un rendement de 3,1% et une distribution du free cash-flow d'environ 57% Une…
- Media Release /Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early…
- Media Release /Shareholders approve 22nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow Overwhelming majority of…
- Media Release /Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and…
- Media Release /New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16…
- Media Release /Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019…
- Key Release /Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced…
- Key Release /Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…